Abstract: Objective To observe the efficacy of entecavir combined with silybin meglumine amine in treatment of patients with chronic hepatitis B （CHB） and non-alcoholic fatty liver disease （NAFLD）. Methods 80 patients with CHB and NAFLD in our hospital were enrolled between January 2015 and January 2016 in this study. Patients were randomly divided into control group and observation group with 40 cases in each group. The patients in control group was treated with entecavir alone and in observation group was given entecavir combined with silybin meglumine amine. The regimen continued in both groups,and we assessed the efficacy at the end of six month treatment. Results At the end of six month treatment,serum alanine aminotransferase and aspartate amonotransferase levels in observation group were significantly lower than those in the control group[（64.3±27.9） U/L vs. （83.7±26.0） U/L,and （42.0±24.5） U/L vs. （57.6±26.6） U/L,respectively,P<0.05 for both];serum levels of PCⅢ,Ⅳ-C,LN and HA in observation group were lower than those in the control group [（106.0±54.5） ng/L vs. （147.6±76.6） ng/L,（69.23±21.24） ng/L vs. （86.74±21.30） ng/L,（119.2±61.2） ng/L vs. （212.7±100.3） ng/L,and （119.2±71.2） ng/L vs. （205.7±91.3） ng/L,respectively,P<0.05 for all];there were no differences as respect to serum HBV DNA and HBsAg levels between the two groups [（2.3±0.9） Ig IU /ml vs. （2.7±1.0） Ig IU /ml,and （4458.0±945.5） S/CO vs. （4744.0±1256.5） S/CO,respectively,P<0.05 for both]. Conclusion The combination of entecavir and silybin meglumine amine is effective in improving liver enzymes and serum indexs of hepatic fibrosis in patients with CHB and NAFLD,but we don’t find any benefit on serum HBsAg eradication by this regimen.

Key words: Hepatitis B, Non-alcoholic fatty liver disease, Entecavir, Silybin meglumine amine, Therapy